HIGHLY SENSITIVE AND RAPID EVALUATION OF PYRIDOSTIGMINE IMPURITY B IN HUMAN PLASMA BY LIQUID CHROMATOGRAPHY COUPLED WITH TANDEM MASS SPECTROMETER AFTER ADMINISTRATION OF PYRIDOSTIGMINE TO HEALTHY VOLUNTEERS IN A PHARMACOKINETIC STUDY

Authors

  • Sambasiva Rao Puram VerGo Clinicals, Mologa de Orora, Corlim, Goa, India.
  • Raman Batheja VerGo Clinicals, Mologa de Orora, Corlim, Goa, India.
  • G Nithya 2Department of Chemistry, School of basic sciences, Vels Institute of science, Technology and advanced studies, Chennai, India

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i6.25038

Keywords:

Pyridostigmine impurity B, Pyridostigmine impurity B in plasma, Pyridostigmine impurity B by liquid chromatography coupled with tandem mass spectrometer, Pyridostigmine, Safety of pyridostigmine metabolite, Pyridostigmine metabolite

Abstract

Objective: Objective of this work is to evaluate the levels in plasma of pyridostigmine impurity B (metabolite of pyridostigmine) in humans after administration of pyridostigmine formulations.

Methods: Plasma concentrations of pyridostigmine impurity B were estimated using by liquid chromatography coupled with electron spray ionization triple quad mass spectrometer technique, lamivudine is used as an internal standard. Multiple reaction at 109.9/95.2 (pyridostigmine impurity B) and 230.2/112.2 (lamivudine) were monitored. Chromatography was optimized using acetonitrile: Buffer (10 millimolar ammonium acetate) (85:15) on an Inertsil C18, 150 mm×4.6 mm, 5 μ analytical column. Linear Calibration curve set between 1.434 ng/ml and 39.637 ng/ml. Sample extraction was conducted using solid phase extraction method using mixed mode cation exchange cartridges. The method was developed on API 4000.

Results: Method was developed, tested for system suitability, carryover, selectivity, matrix effect, intra-inter precision and accuracy, recovery, linearity, and various stabilities in aqueous as well as plasma as matrix. The method was validated for all the above validation parameters mentioned as per European medical agency guideline on method validation.

Conclusions: The method is successfully applied to analyze 1890 subject samples after administration of pyridostigmine 180 mg as per Independent Ethics Committee approved protocol. Incurred sample reanalysis was revealed a great reproducibility of method. Statistical analysis was also conducted to compare test formulation with innovator formulation. Test formulation concentrations of pyridostigmine impurity B are similar to those obtained from innovator formulation.

Downloads

Download data is not yet available.

References

Wikipedia, Pyridostigmine Impurity B, Encyclopedia; 2016. Available from: . [Last accessed on 2017 Aug 07].

Zhao B, Moochhala SM, Lu J, Tan D, Lai DH. Determination of pyridostigmine bromide and its metabolites in biological samples. J Pharm Pharm Sci 2006;9:71-81.

Matsunaga H, Suehiro T, Saita T, Nakano Y, Mori M, Takata K, et al. High-performance liquid chromatographic determination of Pyridostigmine in plasma. J Chromatogr 1987;422:353-5.

Aquilonius SM, Eckernäs SA, Hartvig P, Lindström B, Osterman PO. Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur J Clin Pharmacol 1980;18:423-8.

Ali NW, Abdelaleem EA, Naguib IA, Abdallah FF. Development and validation of a stability-indicating high-performance thin-layer chromatographic method for determination of pyridostigmine bromide in the presence of its alkaline-induced degradation product. J Planar Chromatogr 2015;28:316-22.

Abdelaleem EA, Naguib IA, Abdallah FF, Ali NW. Development and validation of three spectrophotometric methods for determination of pyridostigmine bromide in the presence of its alkaline-induced degradation product. Eur J Chem 2016;6:24-34.

Abu-Qare AW, Abou-Donia MB. A validated HPLC method for the determination of pyridostigmine bromide, acetaminophen, acetylsalicylic acid and caffeine in rat plasma and urine. J Pharm Biomed Anal 2001;26:939-47.

Havel J, Patocka J, Bocaz G. Determination of physostigmine and pyridostigmine in pharmaceutical formulations by capillary electrophoresis. J Cap Elec Microchip Tech 2002;7:107-12.

Taylor T, Hawkins DR, Forrest TJ, Chung H. Pharmacokinetics of pyridostigmine in dogs. J Pharm Sci 1991;80:353-56.

Somani SM, Roberts JB, Wilson A. Pyridostigmine metabolism in man. Clin Pharmacol Ther 1972;13:393-99.

Chan K, Williams NE, Baty JD, Calvey TN. A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma. J Chromatogr 1976;120:349-58.

Madhavi S, Rani AP. Bioanalytical method development and validation for the determination of sofosbuvir from human plasma. Int J Pharm Pharm Sci 2017;9:35-41.

Aruna G, Bharathi K, Prasad K. Development and validation of bioanalytical HPLC method for simultaneous estimation of cilnidipine and nebivolol in human plasma. Int J Pharm Pharm Sci 2017;9:253-9.

Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM270392.pdf. [Last accessed on 2017 Aug 07].

EMA, Pyridostigmine Impurity B, Public Assessment Report; 2009. Available from:. [Last accessed on 2017 Aug 07].

EMA, Note for Guideline on the Investigation of BA/BE; 2000. Available from: [Last accessed on 2017 Aug 07].

EMC, Pyridostigmine Impurity B Specific Product Characteristics; 2012. Available from: [Last accessed on 2017 Aug 07].

Published

07-06-2018

How to Cite

Puram, S. R., R. Batheja, and G. Nithya. “HIGHLY SENSITIVE AND RAPID EVALUATION OF PYRIDOSTIGMINE IMPURITY B IN HUMAN PLASMA BY LIQUID CHROMATOGRAPHY COUPLED WITH TANDEM MASS SPECTROMETER AFTER ADMINISTRATION OF PYRIDOSTIGMINE TO HEALTHY VOLUNTEERS IN A PHARMACOKINETIC STUDY”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 6, June 2018, pp. 353-7, doi:10.22159/ajpcr.2018.v11i6.25038.

Issue

Section

Original Article(s)